Last reviewed · How we verify
70% alcohol
70% alcohol, marketed by Universidad Complutense de Madrid, holds a significant position in the antiseptic market. The key composition patent, set to expire in 2028, provides a strong competitive barrier. The primary risk lies in potential generic competition post-patent expiry.
At a glance
| Generic name | 70% alcohol |
|---|---|
| Also known as | Isopropilic alcohol., Ethanol |
| Sponsor | Universidad Complutense de Madrid |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Surgical Site Preparation in Subjects Undergoing Medical Thoracoscopy (NA)
- CLinical Evaluation of ANtiseptic Skin Preparation in Revision Total Joint Arthroplasty of the Hip and Knee (NA)
- Anterior Iliopsoas Space Block Versus PENG Block on Ease of Positioning for Spinal Anathesia in Patients Undergoing Hip Surgeries (PHASE3)
- Effect of Ice Pack and Warm Gel Pad Use During Drain Removal on Anxiety, Comfort, Physiological Parameters, and Patient Satisfaction Undergoing Open Urological Surgery (NA)
- CD34+ Transplants for Leukemia and Lymphoma (PHASE2)
- CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome (PHASE2)
- Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation (NA)
- Reducing Blood Pressure in Mid-life Adult Binge Drinkers (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 70% alcohol CI brief — competitive landscape report
- 70% alcohol updates RSS · CI watch RSS
- Universidad Complutense de Madrid portfolio CI